AU2019474803A1 - Composition and method for treating hematologic cancers - Google Patents

Composition and method for treating hematologic cancers Download PDF

Info

Publication number
AU2019474803A1
AU2019474803A1 AU2019474803A AU2019474803A AU2019474803A1 AU 2019474803 A1 AU2019474803 A1 AU 2019474803A1 AU 2019474803 A AU2019474803 A AU 2019474803A AU 2019474803 A AU2019474803 A AU 2019474803A AU 2019474803 A1 AU2019474803 A1 AU 2019474803A1
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
cancer
cytotoxic agent
use according
mammalian subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019474803A
Other languages
English (en)
Other versions
AU2019474803A2 (en
AU2019474803A8 (en
Inventor
Mohit Jain
Aru NARENDRAN
Dominic Rodrigues
Lucy SWIFT
Satbir Thakur
Eric A. Wachter
Chunfen ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UTI LP
Provectus Pharmatech Inc
Original Assignee
UTI LP
Provectus Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UTI LP, Provectus Pharmatech Inc filed Critical UTI LP
Publication of AU2019474803A1 publication Critical patent/AU2019474803A1/en
Publication of AU2019474803A8 publication Critical patent/AU2019474803A8/en
Publication of AU2019474803A2 publication Critical patent/AU2019474803A2/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019474803A 2019-11-19 2019-11-19 Composition and method for treating hematologic cancers Pending AU2019474803A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/062184 WO2021101521A1 (en) 2019-11-19 2019-11-19 Composition and method for treating hematologic cancers

Publications (3)

Publication Number Publication Date
AU2019474803A1 true AU2019474803A1 (en) 2022-05-26
AU2019474803A8 AU2019474803A8 (en) 2022-06-16
AU2019474803A2 AU2019474803A2 (en) 2022-07-14

Family

ID=75980032

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019474803A Pending AU2019474803A1 (en) 2019-11-19 2019-11-19 Composition and method for treating hematologic cancers

Country Status (5)

Country Link
JP (1) JP2023506609A (es)
AU (1) AU2019474803A1 (es)
CA (1) CA3158221A1 (es)
MX (1) MX2022005828A (es)
WO (1) WO2021101521A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7648695B2 (en) * 1998-08-06 2010-01-19 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US9107887B2 (en) * 2011-03-10 2015-08-18 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
CN109689056A (zh) * 2016-08-01 2019-04-26 亚尼塔公司 用于治疗癌症的组合
WO2018083635A2 (en) * 2016-11-04 2018-05-11 Auckland Uniservices Limited Tricyclic heterocyclic derivatives and uses thereof

Also Published As

Publication number Publication date
CA3158221A1 (en) 2021-05-27
AU2019474803A2 (en) 2022-07-14
WO2021101521A1 (en) 2021-05-27
AU2019474803A8 (en) 2022-06-16
MX2022005828A (es) 2022-07-04
JP2023506609A (ja) 2023-02-16

Similar Documents

Publication Publication Date Title
US20230159640A1 (en) Carrier-pd-l1 binding agent compositions for treating cancers
RU2756892C2 (ru) Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
JP2020528880A (ja) 併用がん療法
US20180303935A1 (en) A nanomaterial complex comprising graphene oxide associated with a therapeutic agent and methods of use
US20210308091A1 (en) In Vitro and Xenograft Anti-Tumor Activity of a Halogenated-Xanthene Against Refractory Pediatric Solid Tumors
KR20200088374A (ko) 면역요법에 대한 항-종양 면역 반응을 유도하기 위해 표적화된 방사선요법(trt)을 이용하는 방법
JP2017502040A (ja) ペプチド核酸系薬剤を用いて癌を処置するための方法及び組成物
JP6591665B2 (ja) Ｔ−ｄｍ１難治性がん患者のｓｙｄ９８５処置
US11419844B2 (en) Halogenated xanthene composition and method for treating hematologic cancers
BR112021001858A2 (pt) uso de partículas negativamente carregadas em combinação com uma terapia de câncer para o tratamento de câncer ou de uma doença proliferativa
AU2019474803A1 (en) Composition and method for treating hematologic cancers
US20210100896A1 (en) Methods and compositions for stimulating the immune system
JP6854765B2 (ja) 標的への抗癌剤の送達を増加させる方法
US20220296712A1 (en) Methods for treatment using phthalocyanine dye-targeting molecule conjugates
US20210290661A1 (en) Immune modifying particles for the treatment of cancer
RU2794261C2 (ru) Иммуномодифицирующие частицы для лечения рака
US20210236418A1 (en) Composition and Method for Oral Treatment of Leukemia
RU2802962C2 (ru) Композиции и способы лечения рака печени
KR20230171854A (ko) 백혈병의 경구 치료를 위한 조성물 및 방법
WO2022006269A1 (en) Non-intuitive combination of drug delivery carriers of the same drug for synergistic growth delay of solid tumors
CN117615791A (zh) 使用抗体药物缀合物的组合疗法
Sinn et al. Albumin-Based Drug Delivery as Novel
Liu et al. Cure of multidrug-resistant human B-cell lymphoma xenografts by

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 36 , NO 21 , PAGE(S) 2950 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME PROVECETUS PHARMATECH, INC.; UTI LIMITED PARTNERSHIP, APPLICATION NO. 2019474803, UNDER INID (71) CORRECT THE APPLICANT NAME TO PROVECTUS PHARMATECH, INC.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 10 JUN 2022